RGEN earnings call for the period ending September 30, 2019.
News & Analysis: Repligen
The company, which has been built on opportunistic acquisitions, entered the final stretch of 2019 with a record level of cash to deploy.
The year may be drawing to a close, but this biomanufacturing stock -- and any investor interested in it -- has plenty to look forward to.
Sometimes stocks go up, sometimes they go down.
The bioprocessing leader is having a bad day, but there doesn't appear to be any reason to panic.
These businesses offer the potential for above-average returns that could receive a huge helping hand from the power of compound interest.
Investors looking to grow their nest egg should give these three stocks a closer look.
The bioprocess leader keeps growing at an incredible pace thanks to acquisitions and surging customer demand.
RGEN earnings call for the period ending June 30, 2019.
The bioprocess engineering leader continued to deliver spectacular growth and bolster its profitability.